Mithra Pharmaceuticals S.A.

Declaration of Voting Results & Voting Rights Announcements • Jun 5, 2018

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL

INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS (DENOMINATOR)

Liège, Belgium, 05 June 2018 [5:45 pm CET] – Regulated information – In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 2,672,414 new shares on 4 June 2018 in the framework of the private placement publicly announced on 31 May 2018:

• Share capital: €27,555,760.70
• Total number of securities carrying voting rights: 37,639,495 (all ordinary shares)
• Total number of voting rights (= denominator): 37,639,495 (all relating to ordinary shares)
• Number of rights to subscribe securities carrying voting rights not yet issued: 650 warrants issues on 2 March 2015, entitling their holders to subscribe for a total number of 1,072,500 securities carrying voting rights (all ordinary shares)

For more information, please contact:

Investor Relations

Sofie Van Gijsel, IR & VP of Strategy +32 485 19 14 15 investorrelations@mithra.com svangijsel@mithra.com

Press

Consilium Strategic Communications Jonathan Birt, Philippa Gardner, Hendrik Thys mithra@consilium-comms.com +44 2 037 095 700

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com